<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01790490</url>
  </required_header>
  <id_info>
    <org_study_id>#6162</org_study_id>
    <nct_id>NCT01790490</nct_id>
  </id_info>
  <brief_title>Glutamatergic Modulation of Cocaine-related Deficits</brief_title>
  <official_title>The Effect of Ketamine on Reducing Cue Reactivity in Cocaine Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cocaine dependence involves problematic neuroadaptations, such as heightened reactivity to
      cocaine cues, that may be responsive to pharmacological modulation of glutamatergic circuits.
      Despite promising preclinical findings with n-methyl-d-aspartate receptor (NMDAr) modulators,
      studies with human subjects have been unsuccessful to date. The purpose of this investigation
      is to examine the effects of the NMDAr antagonist ketamine, recently found to have potent
      therapeutic effects in humans, on cue-induced craving and impaired motivation for quitting
      cocaine in cocaine dependent participants, 24-hours post-infusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, volunteers will undergo a 9 day inpatient trial during which they will receive
      three counter-balanced infusions (two doses of ketamine and a dose of lorazepam) on three
      separate days in a within-subject, double-blind, controlled design. Of the various glutamate
      antagonists available for human use, ketamine will be utilized because its safety profile,
      pharmacokinetics, and range of tolerable sub-anesthetic dosings have been very well studied.
      Also, ketamine has shown promise in managing opiate and alcohol use disorders in certain
      studies, and may therefore be the most likely glutamate antagonist to dampen cue reactivity
      and increase motivation in cocaine users. If ketamine significantly improves these deficits,
      this would suggest that the drug should be investigated further for potential utility as a
      treatment for cocaine dependence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cue Reactivity</measure>
    <time_frame>Baseline and 24 hours after infusion</time_frame>
    <description>Serial visual analogue scale (VAS) scores for craving elicited by cocaine cue: units on a scale (0-200), high is worse. Scores are obtained at baseline and at 24 hours after the infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Motivation to Quit</measure>
    <time_frame>Baseline and 24 hours post-infusion</time_frame>
    <description>Motivation score obtained from the University of Rhode Island Change Assessment (URICA). Scores are obtained at baseline and at 24 hours after each infusion. The scores are 0-13, with higher scores indicating greater motivation. The analysis is within-subject. Scores included below are means; higher scores represent higher motivation to quit than do lower scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Tolerability</measure>
    <time_frame>immediately after each infusion over 5 days</time_frame>
    <description>Various measures ascertain level of dissociation, abuse liability, and behavioral disturbances.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of Initiating Experimental Drug Misuse</measure>
    <time_frame>4 week follow-up after completion of inpatient phase</time_frame>
    <description>Weekly assessment of drug use by history and urine toxicology</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Physiological Reactivity</measure>
    <time_frame>change across infusions over 9 days</time_frame>
    <description>Assesses level of physiological arousal to cues using galvanic skin response</description>
  </other_outcome>
  <other_outcome>
    <measure>Cocaine Use in Follow-up</measure>
    <time_frame>4-week follow up</time_frame>
    <description>Weekly assessment of cocaine use by urine toxicology and history</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>K1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine 0.41 mg/kg infused over 52 min (K1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>K2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine 0.71 mg/kg infused over 52 min (K2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LZP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lorazepam 2 mg infused over 52 minutes (LZP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 0.41 mg/kg</intervention_name>
    <description>52 minute iv infusion of ketamine 0.41 mg/kg</description>
    <arm_group_label>K1</arm_group_label>
    <other_name>K1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 0.71 mg/kg</intervention_name>
    <description>52 minute iv infusion of ketamine 0.71 mg/kg. This dose follows K1 in all 3 orderings.</description>
    <arm_group_label>K2</arm_group_label>
    <other_name>K2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorazepam 2 mg</intervention_name>
    <description>52 minute infusion of lorazepam 2 mg. This serves as an active control.</description>
    <arm_group_label>LZP</arm_group_label>
    <other_name>LZP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Active free-base cocaine dependence (at least 4 days of use over the past month, with
             at least 1 use per week); if the participant uses through another route (IN, IV), then
             the FB route is dominant (&gt; 80% of occasions).

          2. Physically healthy

          3. No adverse reactions to study medications

          4. 21-52 years of age

          5. Normal body weight

          6. Responsive to drug cues

          7. Capacity to consent

        Exclusion Criteria:

          1. Seeking treatment or abstinence

          2. DSM IV criteria for substance dependence (other than methamphetamine, cocaine,
             cannabis, or nicotine), or DSM IV criteria for abuse of ketamine or lorazepam

          3. DSM-IV criteria for other Axis I psychiatric illness that may make participation
             hazardous such as schizophrenia, schizoaffective disorder, psychosis NOS, MDD,
             psychosis secondary to substances, or bipolar disorder

          4. Delirium, Dementia, Amnesia, Cognitive Disorders, or dissociative disorders

          5. Current suicide risk or a history of suicide attempt within the past 2 years

          6. Current use of prescribed psychotropic medication

          7. Pregnancy, nursing, or had a baby within the past 6 mo.

          8. Heart disease as indicated by history, abnormal ECG, previous cardiac surgery.

          9. Unstable physical disorders which might make participation hazardous such as end-stage
             AIDS, hypertension (&gt;140/90), anemia, active hepatitis or other liver disease, or
             diabetes

         10. &quot;Bad&quot; reaction/experience with prior exposure to ketamine or lorazepam

         11. History of significant violence

         12. First degree relative with a psychotic disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>52 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elias Dakwar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYSPI/Columbia College of Physicians and Surgeons</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carl Hart, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NYSPI/Columbia College of Physicians and Surgeons</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYSPI</name>
      <address>
        <city>NY</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2013</study_first_submitted>
  <study_first_submitted_qc>February 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2013</study_first_posted>
  <results_first_submitted>October 31, 2013</results_first_submitted>
  <results_first_submitted_qc>June 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2016</results_first_posted>
  <last_update_submitted>June 13, 2016</last_update_submitted>
  <last_update_submitted_qc>June 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited using advertisements and were seen at NYSPI.</recruitment_details>
      <pre_assignment_details>Participants were excluded if they could not comply with study procedures or if they were found to be ineligible.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>K1, LZP, and K2</title>
          <description>Ketamine 0.41 (K1) followed by lorazepam (LZP) and then ketamine 0.71. Infusions are separated by 48 hours. This ordering allows for comparison between K1 and LZP, and between the post-K1 additive effects of LZP and K2.</description>
        </group>
        <group group_id="P2">
          <title>LZP, K1, and K2</title>
          <description>LZP followed by K1 and then K2. Infusions are separated by 48 hours. This order allows for comparison between LZP and K1.</description>
        </group>
        <group group_id="P3">
          <title>K1, K2, and LZP</title>
          <description>K1 followed by K2 and then LZP. Infusions are separated by 48 hours. This allows for within-subject comparison of the post-K1 additive effects of K2 and LZP.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>K1, LZP, and K2</title>
          <description>Ketamine 0.41 (K1) followed by lorazepam (LZP) and then ketamine 0.71. Infusions are separated by 48 hours. This ordering allows for comparison between K1 and LZP, and between the post-K1 additive effects of LZP and K2.</description>
        </group>
        <group group_id="B2">
          <title>LZP, K1, and K2</title>
          <description>LZP followed by K1 and then K2. Infusions are separated by 48 hours. This order allows for comparison between LZP and K1.</description>
        </group>
        <group group_id="B3">
          <title>K1, K2, and LZP</title>
          <description>K1 followed by K2 and then LZP. Infusions are separated by 48 hours. This allows for within-subject comparison of the post-K1 additive effects of K2 and LZP.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.8" spread="9"/>
                    <measurement group_id="B2" value="48.2" spread="6.1"/>
                    <measurement group_id="B3" value="44.2" spread="8.2"/>
                    <measurement group_id="B4" value="47.5" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Cue Reactivity</title>
        <description>Serial visual analogue scale (VAS) scores for craving elicited by cocaine cue: units on a scale (0-200), high is worse. Scores are obtained at baseline and at 24 hours after the infusion.</description>
        <time_frame>Baseline and 24 hours after infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Infusion 0.41 mg/kg Over 52 Minutes (K1)</title>
            <description>Ketamine 0.41 mg/kg infused over 52 min (K1)
Ketamine 0.41 mg/kg: 52 minute iv infusion of ketamine 0.41 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Ketamine Infusion 0.71 mg/kg Over 52 Minutes (K2)</title>
            <description>Ketamine 0.71 mg/kg infused over 52 min (K2)
Ketamine 0.71 mg/kg: 52 minute iv infusion of ketamine 0.71 mg/kg. This dose follows K1 in all 3 orderings.</description>
          </group>
          <group group_id="O3">
            <title>Lorazepam Infusion 2 mg/kg Over 52 Minutes (LZP)</title>
            <description>Lorazepam 2 mg infused over 52 minutes (LZP)
Lorazepam 2 mg: 52 minute infusion of lorazepam 2 mg. This serves as an active control.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cue Reactivity</title>
          <description>Serial visual analogue scale (VAS) scores for craving elicited by cocaine cue: units on a scale (0-200), high is worse. Scores are obtained at baseline and at 24 hours after the infusion.</description>
          <units>units on a scale (0-200), high is worse</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126" spread="66"/>
                    <measurement group_id="O2" value="18" spread="13"/>
                    <measurement group_id="O3" value="16" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Motivation to Quit</title>
        <description>Motivation score obtained from the University of Rhode Island Change Assessment (URICA). Scores are obtained at baseline and at 24 hours after each infusion. The scores are 0-13, with higher scores indicating greater motivation. The analysis is within-subject. Scores included below are means; higher scores represent higher motivation to quit than do lower scores.</description>
        <time_frame>Baseline and 24 hours post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Infusion 0.41 mg/kg Over 52 Minutes (K1)</title>
            <description>Ketamine 0.41 (K1) followed by lorazepam (LZP) and then ketamine 0.71. Infusions are separated by 48 hours. This ordering allows for comparison between K1 and LZP, and between the post-K1 additive effects of LZP and K2.</description>
          </group>
          <group group_id="O2">
            <title>Lorazepam Infusion 2 mg/kg Over 52 Minutes (LZP)</title>
            <description>LZP followed by K1 and then K2. Infusions are separated by 48 hours. This order allows for comparison between LZP and K1.</description>
          </group>
          <group group_id="O3">
            <title>Lorazepam Infusion 2 mg/kg Over 52 Minutes (LZP) Following K1</title>
            <description>Infusions are separated by 48 hours. This allows for within-subject comparison of the post-K1 additive effects of K2 and LZP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Motivation to Quit</title>
          <description>Motivation score obtained from the University of Rhode Island Change Assessment (URICA). Scores are obtained at baseline and at 24 hours after each infusion. The scores are 0-13, with higher scores indicating greater motivation. The analysis is within-subject. Scores included below are means; higher scores represent higher motivation to quit than do lower scores.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.35" lower_limit="2.12" upper_limit="6.01"/>
                    <measurement group_id="O2" value="3.2" lower_limit="1.1" upper_limit="5.87"/>
                    <measurement group_id="O3" value="4.2" lower_limit="2.12" upper_limit="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Tolerability</title>
        <description>Various measures ascertain level of dissociation, abuse liability, and behavioral disturbances.</description>
        <time_frame>immediately after each infusion over 5 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk of Initiating Experimental Drug Misuse</title>
        <description>Weekly assessment of drug use by history and urine toxicology</description>
        <time_frame>4 week follow-up after completion of inpatient phase</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Physiological Reactivity</title>
        <description>Assesses level of physiological arousal to cues using galvanic skin response</description>
        <time_frame>change across infusions over 9 days</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cocaine Use in Follow-up</title>
        <description>Weekly assessment of cocaine use by urine toxicology and history</description>
        <time_frame>4-week follow up</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ketamine 0.41 (K1)</title>
          <description>Ketamine 0.41 (K1) over 52 minutes</description>
        </group>
        <group group_id="E2">
          <title>Lorazepam 2 mg (LZP)</title>
          <description>Lorazepam 2 mg (LZP) over 52 minutes</description>
        </group>
        <group group_id="E3">
          <title>Ketamine 0.71 (K2)</title>
          <description>Ketamine 0.71 mg/kg over 52 minutes (K2)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elias Dakwar, MD</name_or_title>
      <organization>NYSPI</organization>
      <phone>(646) 774-8728</phone>
      <email>dakware@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

